I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $476.3M | ||||
Company | Location |
Date | Amt. (M) |
Details |
AbAg |
Chilly Mazarin, France |
1/19/06 |
€6 |
The Series B financing was led by Innoven Partners, and included Societe Generale Asset Management |
Acceleron |
Cambridge, Mass. |
1/5/06 |
$8 |
The financing was provided by Hercules Technology Growth Capital Inc. |
Accium |
Seattle |
1/5/06 |
$3 |
The financing was provided by WRF Capital |
Adlyfe Inc. |
Rockville, Md. |
1/17/06 |
$3.3 |
Investors in the Series A financing included Canaan Partners and Burrill Associates |
Athenix Corp. |
Research Triangle Park, N.C. |
1/6/06 |
$13 |
Finistere Partners led the Series C round, which included Intersouth Partners, Polaris Venture Partners, Boston Millennia Partners, Hunt Ventures and Eastman Ventures |
Avidex Ltd. |
Oxford, UK |
1/4/06 |
£5 ($8.8) |
Syngenta AG acquired a minority equity stake in Avidex with the £5M investment |
Avid Radio- |
Philadelphia |
1/5/06 |
$8.9 |
The Series A financing was led by Pfizer's Strategic Investments Group and included Lilly Ventures, RK Ventures LLC and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania |
Axordia Ltd. |
Sheffield, UK |
1/20/06 |
£0.42 $0.75) |
Biofusion purchased 5% of Axordia in the deal, increasing its stake to 36% |
CanBas Co. |
Numazu, Japan |
1/6/06 |
$20 |
This Series D financing was co-led by NIF SMBC Ventures and Mitsui Ventures and included Nikko antfactory KK, MBL Venture Capital, Mizuho Capital, Nomura Securities and Marubeni |
Cetek Corp. |
Marlborough, Mass. |
1/3/06 |
$10 |
Investing in the Series D financing were Argonaut Private Equity, Ventry Industries LLC, Gainesbourgh Investments, James L. Waters and Stata Ventures, all existing investors |
Chlorogen Inc. |
St. Louis |
1/19/06 |
$6 |
The Series B financing included new investor Finistere Partners along with existing investors Burrill & Co., Prolog Ventures, Redmont Venture Partners and Harris & Harris Group |
CoLucid |
Indianapolis |
1/17/06 |
$16.5 |
The Series A financing was co-led by Domain Associates and Pappas Ventures and included Triathlon Medical Ventures and Pearl Street Venture Funds |
CureVac GmbH |
Tubingen, Germany |
1/18/06 |
€22 ($26.4) |
New investors DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG participated in the Series B financing, which will total up to €22M |
EraGen |
Madison, Wis. |
1/9/06 |
$12 |
The Series A financing was led by First Analysis Corp. and Prolog Ventures and included new investor Stonehenge Capital and existing investor Novartis Venture Fund |
GlobeImmune |
Denver |
1/10/06 |
$4.1 |
GlobeImmune added $4.1M to the $34.3M raised in November in a Series B financing; investors included PAC-LINK Bio Venture Capital, China Investment and Development and Yasuda Enterprise Development |
Guava |
Hayward, Calif. |
1/19/06 |
$5.5 |
Guava obtained the secured debt financing from Hercules Technology Growth Capital Inc.; it also obtained a one-year credit line of $4.5M from Hercules |
Hawaii Biotech |
Honolulu |
1/9/06 |
$7.8 |
The Series C financing round was led by company Chairman Nick Mitsakos and included private investors |
ImmunoBiology |
Cambridge, UK |
1/23/06 |
£5.5 ($9.8) |
The Series C financing was led by Inventages Venture Capital Investments Inc. and included Biosciences VTC and existing investors Avlar BioVentures, Oxford Technology VCT, Generics Asset Management and Yorkshire Fund Managers |
Ipsat |
Helsinki, Finland |
1/25/06 |
€3 ($3.7) |
The funding was provided by InnovationsKapital |
MAP Pharmaceuticals |
Mountain View, |
1/25/06 |
$25.25 |
The Series C financing was led by Brookside Capital and included previous investors Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Bay City Capital and Skyline Ventures, as well as Alexandria Real Estate Equities |
Metabolon Inc. |
Research Triangle Park, N.C. |
1/18/06 |
$8 |
The Series B financing was led by Sevin Rosen Funds and included existing investors The Aurora Funds and The Trelys Funds and new investor Harris & Harris Group |
Nabriva |
Vienna, Austria |
1/31/06 |
€42 ($50.7) |
Nabriva was spun off from Sandoz GmbH; Nomura Phase4 Ventures led the Series A round, which included HBM, the Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund |
Novacea Inc. |
South San Francisco |
1/4/06 |
$25 |
Investors in the $25M second tranche of the Series C financing included Apax Partners, Domain Associates, New Enterprise Associates, ProQuest Investments, Versant Ventures and Sofinnova Ventures; $35M was raised in the first Series C tranche in January 2004 |
Ocera |
San Diego |
1/17/06 |
$14.5 |
The Series A financing was co-led by Domain Associates and Thomas, McNerney & Partners |
OcuCure |
Roanoke, Va. |
1/31/06 |
ND |
The undisclosed investment was provided by the Carilion Biomedical Institute |
OptiNose A/S |
Oslo, Norway |
1/9/06 |
ND |
WFD Ventures Ltd. provided the undisclosed funding |
Proacta Inc. |
San Diego |
1/24/06 |
$12 |
Investing in the Series A financing were GSB Ventures, Endeavour i-Cap, No8 Ventures, Alta Partners, Genentech Inc. and F. Hoffmann-La Roche Ltd. |
Protein Sciences Corp. |
Meriden, Conn. |
1/9/06 |
$6 |
Investing in the round were Diamyd Medical AB, Pacific Rim Ventures Co. Ltd. and a family fund |
Supernus |
Rockville, Md. |
1/12/06 |
$27.5 |
New Enterprise Associates and OrbiMed Advisors provided funding for the new company, which acquired the product formulation and development business of Shire Laboratories Inc. |
Symphogen |
Copenhagen, Denmark |
1/8/06 |
$25 |
Company said it completed the initial closing of a Series D financing; investors included LD Pensions, Essex Woodlands Health Ventures, Scandinavian Life Science Venture, Novo A/S, Vaekstfonden and Takeda Research Investment Inc. |
Theregen Co. |
San Francisco |
1/17/06 |
$1.5 |
Sanderling Ventures invested in the Series A financing and would add more if milestones are reached |
TiGenix NV |
Leuven, Belgium |
1/5/06 |
€16 ($19.4) |
The Series B financing round was led by ING Corporate Finance, and included HSS Ventures, ITX Corp., Banque Generale de Luxembourg, Baekelands Fonds 2, SRIW and Partners@Venture, as well as all existing investors |
Tioga |
San Diego |
1/6/06 |
$24 |
Founding investor Forward Ventures led the Series A financing, which also included New Leaf Venture Partners and BB Biotech Ventures II |
Vasopharm |
Wurzburg, Germany |
1/30/06 |
€9.7 ($11.7) |
The Series B financing was led by EMBL Ventures and included other new investors Bayern Kapital and KfW and existing investors Future Capital AG, Entrepreneurs Fund, 3i Group Investments LP and private investors |
XDx Inc. |
South San Francisco |
1/5/06 |
$26.5 |
Duff, Ackerman & Goodrich led the Series E round, which included Intel Capital and existing inves- tors Kleiner Perkins Caufield & Byers, Texas Pacific Group Ventures, the Sprout Group, Burrill & Co., Integral Capital Partners and Bay Area Equity Fund |
Xytis Inc. |
Irvine, Calif. |
1/9/06 |
$24.5 |
The Series B round was led by Sanderling Ventures and included Atlas Venture, Ventech and CDC Entreprises Innovation; the company resulted from the merger of Xytis Pharmaceuticals Ltd. and Remergent Inc. |
|
| ||||
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
